ZTZhenhua Tong

Zhenhua Tong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhenhua Tong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Xingshun Qi

    Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China

    2 shared publications
  • Zhaohui Bai

    Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

    2 shared publications
  • Bing Wang

    Department of Endocrinology and Metabolism, The Central Hospital of Dalian University of Technology, Dalian 116000, China

    1 shared publication
  • Haijuan Yao

    Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China

    1 shared publication
  • Hanyang Lin

    Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China

    1 shared publication
  • Hongxin Chen

    Affiliated Hospital of Nanjing University of Chinese Medicine

    1 shared publication

Latest Publications

  • Open Access

    Diagnostic utility of CT for abdominal injury in the military setting

    by Zhaohui Bai, Bing Wang, Jing Tian, Zhenhua Tong, Hui Lu, Xingshun Qi

    Background: It is critical to accurately identify patients with abdominal injury who truly need to undergo laparotomy during the war in timely fashion. The diagnostic utility of computed tomography (CT) for evaluating abdominal injury in the military setting remains uncertain. Methods: PubMed, EMBASE, and Cochrane Library databases were searched. Meta-analyses were performed by using a random-effect model. We pooled the area under the summary receiver operating characteristic curves with standard errors, the Q indexes with standard errors, the sensitivities with 95% confidence intervals (CIs), the specificities with 95% CIs, the positive likelihood ratios with 95% CIs, the negative likelihood ratios with 95% CIs, and the diagnostic odds ratios with 95% CIs. The heterogeneity among studies were evaluated by the I 2 and P value. Results: Overall, 5 retrospective studies were included. The area under the summary receiver operating characteristic curve was 0.9761 ± 0.0215 and the Q index was 0.9302 ± 0.0378. The pooled sensitivity was 0.97 (95% CI = 0.92–0.99) without a significant heterogeneity among studies (I 2 = 0%, P = .4538). The pooled specificity was 0.95 (95% CI = 0.93–0.97) with a significant heterogeneity among studies (I 2 = 90.6%, P < .0001). The pooled positive likelihood ratio was 10.71 (95% CI: 2.91–39.43) with a significant heterogeneity among studies (I 2 = 89.2%, P < .0001). The pooled negative likelihood ratio was 0.07 (95% CI = 0.02–0.27) with a significant heterogeneity among studies (I 2 = 57.5%, P = .0516). The pooled diagnostic odds ratio was 177.48 (95% CI = 18.09–1741.31) with a significant heterogeneity among studies (I 2 = 75.9%, P = .0023). Conclusion: Diagnostic accuracy of CT for abdominal injury is excellent in the military setting. Further work should explore how to shrink CT equipment for a wider use in wartime.


  • Open Access

    Efficacy of Xuebijing Injection for Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Hongxin Chen, Zhaohui Bai, Hongyu Li, Yanyan Wu, Haijuan Yao, Le Wang, Hanyang Lin, Zhenhua Tong, Rolf Teschke, Xingshun Qi

    Background and Aim. Xuebijing injection is a traditional Chinese medicine compound for the improvement of systemic inflammation response. This meta-analysis of randomized controlled trials (RCTs) aimed to explore the clinical efficacy and safety of Xuebijing injection for the treatment of acute pancreatitis (AP). Methods. PubMed Medline, Embase, Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine disc, VIP, and Wanfang databases were searched. The primary outcome was treatment response. The secondary outcomes included changes in clinical and laboratory indicators and incidence of AP-related complications. Meta-analyses were performed by using a random-effect model. Risk ratios (RRs) with 95% confidence intervals (CIs) or weighted mean differences (WMDs) with 95% CIs were calculated. Results. Overall, 23 RCTs were included. The rates of overall (RR = 1.16; 95% CI = 1.12 to 1.20; ) and complete (RR = 1.40; 95% CI = 1.30 to 1.50; ) responses were significantly higher in the Xuebijing injection group. After treatment, the levels of interleukin-6 (WMD = −18.22; 95% CI = −23.36 to −13.08; ), tumor necrosis factor-α (WMD = −16.44; 95% CI = −20.49 to −12.40; ), serum amylase (WMD = −105.61; 95% CI = −173.77 to −37.46; ), white blood cell (WMD = −1.51; 95% CI = −1.66 to −1.36; ), and C-reactive protein (WMD = −11.05; 95% CI = −14.32 to −7.78; ) were significantly lower in the Xuebijing injection group. Abdominal pain (WMD = −1.74; 95% CI = −1.96 to −1.52; ), abdominal distension (WMD = −1.56; 95% CI = −2.07 to −1.04; ), gastrointestinal function (WMD = −2.60; 95% CI = −3.07 to −2.13; ), body temperature (WMD = −2.16; 95% CI = −2.83 to −1.49; ), serum amylase level (WMD = −1.81; 95% CI = −2.66 to −0.96; ), and white blood cell (WMD = −2.16; 95% CI = −2.99 to −1.32; ) recovered more rapidly in the Xuebijing injection group. The incidence of multiple organ dysfunction syndrome (RR = 0.18; 95% CI = 0.05 to 0.62; ), pancreatic pseudocyst (RR = 0.17; 95% CI = 0.04 to 0.77; <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" width="21.918pt"...